FOLH1 and glioblastoma: While no data are currently available concerning this combination or the efficacy of GNOS-PV02, INO-9012 is in an additional phase I/II clinical trial in glioblastoma combined with the DNA vaccine INO-5401, which expresses the cancer antigens human telomerase reverse transcriptase (hTERT), Wilms’ tumor gene 1 (WT-1) and prostate-specific membrane antigen (PSMA).